(MENAFN- Straits Research)
Clinical Oncology Next Generation Sequencing Market Size Analysis
The global clinical oncology next generation sequencing market size was valued at USD 628.45 million in 2025 and is projected to grow from USD 695.95 million in 2026 to USD 1574.02 million by 2034, registering a CAGR of 10.74% during the forecast period from 2026 to 2034. North America dominated the clinical oncology next-generation sequencing market with a market share of 42.35% in 2025.
Clinical oncology next-generation sequencing (NGS) refers to the use of advanced sequencing technologies to analyze tumor DNA and RNA for identifying genetic mutations, biomarkers, and other molecular alterations. It supports cancer diagnosis, tumor profiling, treatment selection, companion diagnostics, and disease monitoring, enabling more personalized and precision-based oncology care.
Clinical Oncology Next-Generation Sequencing Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 628.45 Million
2026 Market Size: USD 695.95 Million
2034 Projected Market Size: USD 1574.02 Million
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 10.74%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 42.35%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 17.38%
Segment Insights
By Applications
Leading Segment: Companion Diagnostics
Market Share in 2025: 44.87%
By Workflow
Fastest-Growing Segment: NGS Data Analysis
CAGR: 16.84% (2026–2034)
By Technology
Leading Segment: Targeted Sequencing and Re-Sequencing
Market Share in 2025: 46.64%
By End-User
Fastest-Growing Segment: Diagnostic laboratories
CAGR: 15.74% (2026–2034)
Download a Free Sample To learn more about this report,
Clinical Oncology Next-Generation Sequencing Market Trends
Growing Adoption of Precision Oncology and Comprehensive Genomic Profiling
The clinical oncology next-generation sequencing market is increasingly benefiting from the adoption of precision oncology, as healthcare providers use genomic information to identify actionable mutations and guide targeted cancer therapies. Comprehensive genomic profiling and companion diagnostics are becoming increasingly important in clinical decision-making, supporting the broader integration of NGS into routine oncology workflows.
In June 2026, the FDA expanded the labeling for Illumina's TruSight Oncology Comprehensive assay, which uses targeted NGS to analyze 517 genes and provide tumor profiling and companion diagnostic information for patients with solid tumors.
Expansion of Liquid Biopsy and Minimal Residual Disease Testing
Another important clinical oncology NGS market trend is the increasing adoption of liquid biopsy and circulating tumor DNA testing. Blood-based NGS enables less-invasive genomic analysis and is gaining applications in treatment selection, disease monitoring, and minimal residual disease detection. The expansion of clinical validation and regulatory approvals is supporting broader use of liquid biopsy in oncology.
In May 2026, the FDA approved Natera's Signatera CDx, an NGS-based assay for detecting circulating tumor DNA and molecular residual disease in patients with muscle-invasive bladder cancer, supporting the expansion of blood-based NGS in clinical oncology.
Clinical Oncology Next-Generation Sequencing Market Dynamics
Market Drivers
Growing Demand for Precision Oncology
The increasing adoption of precision oncology is driving demand for clinical NGS as healthcare providers use genomic information to identify actionable mutations and select targeted therapies. Rising cancer incidence, advances in molecular diagnostics, and increasing use of companion diagnostics are expanding the role of NGS in routine cancer management.
In June 2026, clinical oncology research continued to highlight NGS as an important tool for identifying actionable alterations that can influence cancer diagnosis, risk assessment, and treatment selection.
Market Restraints
High Testing Costs and Inconsistent Reimbursement
The cost of sequencing, bioinformatics, laboratory infrastructure, and clinical interpretation can limit the adoption of NGS, particularly in cost-sensitive healthcare systems. Inconsistent reimbursement policies can further restrict access even when genomic testing demonstrates clinical utility, creating differences in testing adoption across patient populations and regions.
In June 2026, research presented at the ASCO Annual Meeting highlighted inconsistent payer coverage and inadequate reimbursement as continuing barriers to routine NGS testing despite its clinical utility in precision oncology.
Market Opportunities
Expansion of Liquid Biopsy and Minimal Residual Disease Testing
The increasing use of circulating tumor DNA and liquid biopsy technologies is creating new opportunities for clinical oncology NGS. Blood-based genomic testing can support treatment selection, recurrence monitoring, and minimal residual disease assessment, particularly when tissue samples are unavailable or insufficient.
In March 2026, CMS issued a national coverage determination for Natera Signatera ctDNA monitoring in colorectal cancer post-surgical surveillance, creating a significant reimbursement opportunity for genomic-based minimal residual disease monitoring.
Market Challenges
Complexity of Genomic Data Interpretation and Clinical Integration
The growing volume and complexity of NGS data create challenges related to variant interpretation, data management, reporting standards, clinical decision-making, and integration with healthcare information systems. Shortages of skilled bioinformatics professionals and differences in reporting practices can also slow the integration of NGS into routine clinical workflows.
In August 2026, research on molecular profiling of solid tumors highlighted data-management, reporting harmonization, and healthcare funding as important barriers to broader implementation of NGS-based comprehensive genomic profiling.
Clinical Oncology Next-Generation Sequencing Market Segmentation Analysis
By Applications
Companion Diagnostics Segment Dominated the Market with 44.87% Share in 2025
The companion diagnostics segment dominated the clinical oncology next-generation sequencing market with a 44.87% share in 2025, reaching USD 281.99 million, and is projected to grow at a CAGR of 16.12% during 2026–2034. Screening accounted for a 38.46% share, reaching USD 241.70 million, while other applications represented 16.67%, reaching USD 104.76 million.
The growing use of genomic biomarkers to guide targeted cancer therapies is supporting demand for companion diagnostics. NGS enables the identification of multiple molecular alterations from tumor samples, helping healthcare providers select appropriate treatments and improve precision oncology outcomes.
Request Customization to receive a tailored report.
By Workflow
NGS Data Analysis Segment is Projected to Grow at a CAGR of 16.84%
The NGS sequencing segment accounted for a 45.39% share of the clinical oncology next-generation sequencing market in 2025, reaching USD 285.25 million, and is projected to grow at a CAGR of 14.95% during 2026–2034. NGS pre sequencing represented 31.28%, reaching USD 196.58 million, while NGS data analysis accounted for 23.33%, reaching USD 146.62 million, and is projected to grow at the fastest CAGR of 16.84%.
The increasing volume and complexity of genomic data generated during oncology testing is driving demand for advanced data analysis solutions. Bioinformatics platforms and computational tools are increasingly being used to interpret sequencing results, identify clinically relevant mutations, and support treatment decisions.
By Technology
Targeted Sequencing and Re-Sequencing Segment Dominated the Market with 46.64% Share in 2025
The targeted sequencing and re-sequencing segment dominated the clinical oncology next-generation sequencing market with a 46.64% share in 2025, reaching USD 293.11 million, and is projected to grow at a CAGR of 15.26% during 2026–2034. Whole exome sequencing accounted for a 28.74% share, reaching USD 180.62 million, while whole genome sequencing represented 24.62%, reaching USD 154.72 million.
Targeted sequencing remains widely used in clinical oncology because it enables efficient analysis of specific cancer-related genes and mutations while requiring less sequencing data than broader genomic approaches. Increasing adoption of targeted cancer therapies and biomarker testing is supporting segment growth.
By End-User
Diagnostic Laboratories Segment is Projected to Grow at a CAGR of 15.74%
The diagnostic laboratories segment accounted for a 47.26% share of the clinical oncology next-generation sequencing market in 2025, reaching USD 297.01 million, and is projected to grow at a CAGR of 15.74% during 2026–2034. Hospitals accounted for a 39.18% share, reaching USD 246.23 million, while other end-users represented 13.56%, reaching USD 85.22 million.
Diagnostic laboratories are increasingly adopting NGS platforms to support molecular tumor profiling, biomarker identification, and precision cancer testing. Growing demand for comprehensive genomic testing and the expansion of specialized oncology diagnostics are supporting the increasing use of NGS in laboratory settings.
Speak to an Analyst to discuss market opportunities.
Clinical Oncology Next-Generation Sequencing Market Regional Outlook
North America Clinical Oncology Next-Generation Sequencing Market Analysis
North America dominated the clinical oncology next-generation sequencing market with a 42.35% share in 2025, reaching USD 266.15 million, and is projected to grow at a CAGR of 13.84% during 2026–2034. The region's leading position is supported by advanced molecular diagnostics infrastructure, high adoption of precision oncology, strong cancer research activity, and established reimbursement pathways for genomic testing. The presence of major sequencing and biotechnology companies and widespread use of companion diagnostics are also supporting regional growth.
United States Clinical Oncology Next-Generation Sequencing Market Insights
The US market is supported by advanced healthcare infrastructure, substantial investment in cancer genomics, widespread adoption of tumor profiling, and strong integration of NGS into precision oncology. Supportive regulatory frameworks, reimbursement for genomic testing, and the presence of leading sequencing companies are further contributing to market expansion.
Canada Clinical Oncology Next-Generation Sequencing Market Insights
Canada's market is supported by expanding access to molecular diagnostics, public healthcare investment, and growing adoption of genomic testing in cancer care. Increasing integration of precision medicine and expanding oncology testing infrastructure are creating further opportunities for clinical NGS adoption.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Clinical Oncology Next-Generation Sequencing Market Analysis
Europe accounted for 27.18% of the clinical oncology next-generation sequencing market in 2025, reaching USD 170.81 million, and is projected to grow at a CAGR of 14.21% during 2026–2034. Growth is supported by increasing adoption of personalized medicine, national cancer genomics initiatives, advanced healthcare infrastructure, and expanding access to molecular diagnostics. Collaboration between research institutions, healthcare providers, and biotechnology companies is also supporting the development of NGS-based oncology applications.
United Kingdom Clinical Oncology Next-Generation Sequencing Market Insights
The UK market is supported by government-backed genomics initiatives, strong precision oncology research, and established healthcare and diagnostic infrastructure. Increasing use of genomic testing for cancer classification, treatment selection, and biomarker identification is supporting the integration of NGS into clinical oncology.
Germany Clinical Oncology Next-Generation Sequencing Market Insights
Germany's market benefits from well-established healthcare infrastructure, strong investment in cancer genomics research, and increasing adoption of precision medicine. Growing use of advanced molecular diagnostics and NGS testing for tumor profiling and therapy selection is supporting market development.
Asia Pacific Clinical Oncology Next-Generation Sequencing Market Analysis
Asia Pacific accounted for 21.64% of the clinical oncology next-generation sequencing market in 2025, reaching USD 136.00 million, and is projected to grow at the fastest CAGR of 17.38% during 2026–2034. Growth is supported by rising cancer prevalence, expanding healthcare infrastructure, increasing adoption of precision medicine, and growing investment in genomic research. Government-supported genomics initiatives and expanding clinical laboratory networks are further accelerating NGS adoption across the region.
China Clinical Oncology Next-Generation Sequencing Market Insights
China's market is supported by increasing cancer incidence, expanding molecular diagnostics infrastructure, and growing government and industry investment in genomic medicine. Increasing adoption of precision oncology, targeted therapies, and clinical sequencing is supporting the expansion of NGS-based cancer testing.
Japan Clinical Oncology Next-Generation Sequencing Market Insights
Japan's market benefits from advanced healthcare infrastructure, established oncology centers, and increasing adoption of genomic medicine. Growing use of NGS for tumor profiling and companion diagnostic testing, supported by healthcare coverage frameworks for targeted oncology therapies, is contributing to market growth.
Middle East and Africa Clinical Oncology Next-Generation Sequencing Market Analysis
Middle East and Africa accounted for 3.71% of the clinical oncology next-generation sequencing market in 2025, reaching USD 23.32 million, and is projected to grow at a CAGR of 11.82% during 2026–2034. Growth is supported by improving healthcare infrastructure, increasing awareness of precision medicine, rising cancer burden, and gradual expansion of advanced molecular diagnostic services. Growing investment in genomic testing and specialized oncology centers is also creating opportunities for NGS adoption.
UAE Clinical Oncology Next-Generation Sequencing Market Insights
The UAE market is supported by investments in advanced healthcare infrastructure, increasing adoption of precision medicine, and growing demand for specialized oncology diagnostics. The expansion of modern hospitals, diagnostic laboratories, and genomic testing capabilities is supporting the adoption of NGS technologies.
South Africa Clinical Oncology Next-Generation Sequencing Market Insights
South Africa's market is supported by expanding diagnostic laboratory capabilities, increasing cancer research activity, and growing awareness of molecular testing. Improvements in healthcare infrastructure and increasing demand for advanced cancer diagnostics are contributing to the gradual adoption of clinical oncology NGS.
Clinical Oncology Next-Generation Sequencing Market Competitive Landscape
The clinical oncology next-generation sequencing market is competitive, with leading companies focusing on sequencing platforms, oncology panels, companion diagnostics, bioinformatics, molecular profiling, and integrated genomic testing solutions. Key players include Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Hoffmann-La Roche Ltd, QIAGEN N.V., Foundation Medicine, Inc., Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Becton, Dickinson and Company, and PacBio. Companies are increasingly expanding targeted sequencing, comprehensive genomic profiling, liquid biopsy, and data-analysis capabilities to support precision oncology and biomarker-driven treatment decisions. Illumina, for example, offers oncology-focused NGS panels and integrated sequencing and bioinformatics solutions for cancer research and clinical applications.
Foundation Medicine, Inc.
Foundation Medicine is strengthening its position through comprehensive genomic profiling and NGS-based companion diagnostic solutions for precision oncology. Its FoundationOne CDx and FoundationOne Liquid CDx platforms support the identification of genomic alterations and biomarkers that can help guide targeted therapy decisions across multiple cancer types.
In June 2026, Foundation Medicine received FDA approval for FoundationOne CDx as a companion diagnostic for Itovebi (inavolisib), expanding its use for identifying patients with PIK3CA-mutated hormone receptor-positive, HER2-negative breast cancer.
List of Key and Emerging Players in Clinical Oncology Next Generation Sequencing Market
Illumina, Inc.
Thermo Fisher Scientific Inc
Agilent Technologies, Inc.
Hoffmann-La Roche Ltd
QIAGEN N.V.
Foundation Medicine, INC.
Bio-Rad Laboratories, Inc.
PerkinElmer, Inc.
Becton, Dickinson and Company
PacBio
Oxford Nanopore Technologies plc.
Takara Bio Inc.
Zymo Research Corporation
G-know Me
PerkinElmer
Key Industry Developments
July 2026: CareDx completed the acquisition of Naveris, expanding its precision oncology portfolio with the NavDx® molecular residual disease test for HPV-related cancers. The acquisition strengthens its oncology diagnostics and NGS-based testing capabilities.
June 2026: Illumina launched an enhanced clinical oncology sequencing workflow with improved automation and faster turnaround, enabling more efficient genomic profiling for precision cancer diagnostics.
April 2026: Thermo Fisher Scientific expanded its OncomineTM portfolio with new NGS-based assays for comprehensive tumor profiling, supporting precision oncology and targeted therapy selection.
February 2026: QIAGEN introduced an advanced oncology workflow integrating NGS library preparation with bioinformatics solutions to improve clinical cancer testing efficiency and reporting accuracy.
Report Scope
Comments
No comment